Press release
Hepatitis D Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Eiger Biopharmaceuticals, Arrowhead Pharmaceuticals, Antios Therapeutics, PharmaEssentia, REPLICor, Soma
Hepatitis D Pipeline Insights 2024
Hepatitis D Overview:
Hepatitis D, or "delta hepatitis," is a liver infection caused by the hepatitis D virus (HDV). It only occurs in individuals who are also infected with the hepatitis B virus. The virus is transmitted when blood or other bodily fluids from an infected person enter the body of someone who is not infected. Hepatitis D can manifest as an acute, short-term infection or progress to a long-term, chronic condition. It can lead to severe symptoms and significant illness, potentially causing permanent liver damage and even death. People can be infected with both hepatitis B and D simultaneously (coinfection) or contract hepatitis D after being infected with hepatitis B (superinfection). While there is no specific vaccine for hepatitis D, vaccination against hepatitis B also provides protection against hepatitis D infection.
Request for a detailed insights report on Hepatitis D pipeline insights @ https://www.delveinsight.com/report-store/hepatitis-d-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Hepatitis D Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hepatitis D Therapeutics Market.
Key Takeaways from the Hepatitis D Pipeline Report
DelveInsight's Hepatitis D pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Hepatitis D treatment.
In October 2024, Bluejay Therapeutics announces upcoming data presentations on Chronic Hepatitis D (CHD) and Chronic Hepatitis B (CHB) at the 2024 American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®.
In September 2023, Eiger BioPharmaceuticals announced the discontinuation of its Phase III LIMT-2 study of peginterferon lambda in patients with chronic hepatitis D. This decision was made following a recommendation from the Data Safety Monitoring Board (DSMB) after their routine safety review.
Key Hepatitis D companies such as Eiger Biopharmaceuticals, Arrowhead Pharmaceuticals, Antios Therapeutics, PharmaEssentia, REPLICor, SomaGenics, Vir Biotechnology, VLP Biotech, and others are evaluating new drugs for Hepatitis D to improve the treatment landscape.
Promising Hepatitis D pipeline therapies in various stages of development include Lonafarnib, JNJ 73763989, and others.
Hepatitis D Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Hepatitis D Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatitis D treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hepatitis D market.
Download our free sample page report on Hepatitis D pipeline insights @ https://www.delveinsight.com/sample-request/hepatitis-d-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Hepatitis D Emerging Drugs
Lonafarnib: Eiger Biopharmaceuticals
JNJ 73763989: Arrowhead Pharmaceuticals
Hepatitis D Companies
Around six key companies are developing therapies for Hepatitis D. Among them, Eiger Biopharmaceuticals has drug candidates for Hepatitis D in the most advanced stage, specifically phase III.
DelveInsight's report covers around 22+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Hepatitis D pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Hepatitis D Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Hepatitis D Therapies and Key Companies: Hepatitis D Clinical Trials and advancements @ https://www.delveinsight.com/report-store/hepatitis-d-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Hepatitis D Pipeline Therapeutic Assessment
• Hepatitis D Assessment by Product Type
• Hepatitis D By Stage
• Hepatitis D Assessment by Route of Administration
• Hepatitis D Assessment by Molecule Type
Download Hepatitis D Sample report to know in detail about the Hepatitis D treatment market @ Hepatitis D Therapeutic Assessment @ https://www.delveinsight.com/sample-request/hepatitis-d-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Hepatitis D Current Treatment Patterns
4. Hepatitis D - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Hepatitis D Late-Stage Products (Phase-III)
7. Hepatitis D Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hepatitis D Discontinued Products
13. Hepatitis D Product Profiles
14. Hepatitis D Key Companies
15. Hepatitis D Key Products
16. Dormant and Discontinued Products
17. Hepatitis D Unmet Needs
18. Hepatitis D Future Perspectives
19. Hepatitis D Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Hepatitis D Pipeline Reports Offerings: https://www.delveinsight.com/report-store/hepatitis-d-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hepatitis D Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Eiger Biopharmaceuticals, Arrowhead Pharmaceuticals, Antios Therapeutics, PharmaEssentia, REPLICor, Soma here
News-ID: 3812824 • Views: …
More Releases from DelveInsight Business Research LLP
Crohn's Disease Market Report 2034: Epidemiology Data, Pipeline Therapies, Lates …
DelveInsight's "Crohn's Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Crohn's Disease, historical and forecasted epidemiology as well as the Crohn's Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Crohn's Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Crohn's Disease Market Forecast @ https://www.delveinsight.com/report-store/crohns-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Some…
Complicated Urinary Tract Infections Market Report 2034: Epidemiology Data, Pipe …
DelveInsight's "Complicated Urinary Tract Infections Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Complicated Urinary Tract Infections, historical and forecasted epidemiology as well as the Complicated Urinary Tract Infections market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Complicated Urinary Tract Infections market outlook, drug uptake, treatment scenario and epidemiology trends, Click…
Myasthenia Gravis Market Report 2034: Epidemiology Data, Pipeline Therapies, Lat …
DelveInsight's "Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Myasthenia Gravis, historical and forecasted epidemiology as well as the Myasthenia Gravis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myasthenia Gravis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myasthenia Gravis Market Forecast @ https://www.delveinsight.com/report-store/myasthenia-gravis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Some of the…
Gastroesophageal Reflux Disease Market Report 2034: Epidemiology Data, Pipeline …
DelveInsight's "Gastroesophageal Reflux Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Gastroesophageal Reflux Disease, historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Gastroesophageal Reflux Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastroesophageal Reflux Disease…
More Releases for Hepatitis
Is Hepatitis A Vaccine Required?
Hepatitis A Vaccine Market describes its growth, size, share, Forecast and trends to 2025
Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year.
Two types of HAV vaccines are currently available internationally:
1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available…
Hepatitis Drugs Market Is Growing Due to Increasing R&D Investments on Hepatitis …
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market.
Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market
Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest…
Hepatitis B Therapeutics Market Is Driven by Rising Incidence of Hepatitis B In …
Hepatitis B is a life threatening liver infection caused by hepatitis B virus. Adults who get affected by hepatitis B virus for a short time and then get cured is known as acute hepatitis B. Infection that lasts for a long time is known as chronic hepatitis B. Vaccine is the most preferred choice of doctors and physicians to protect people from the disease. The vaccine prevents the infection and…
Hepatitis E Hyperendemicity to Drive Hepatitis E Diagnostic Tests Market Growth
Global Hepatitis E Diagnostic Tests Market: Snapshot
The growing incidence of hepatitis E, a liver disease caused by infection due to the virus hepatitis E virus (HEV), is a leading cause of morbidity and mortality worldwide. There is increasing prevalence of hepatitis E in resource-limited region, such as various countries of Asia Pacific. The people of these regions suffer with frequent water contamination and have limited access to sanitation and hygiene,…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. Global Prevalence of Hepatitis Infection
3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase…
Hepatitis C Drug Pipeline Analysis
“Hepatitis C Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Hepatitis C. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each…
